Treatment outcomes of sexual minority women (SMW) veterans with military sexual trauma (MST).

Psychol TraumaDec 18, 2025 (epub)
Clinical ResearchPsychiatryOpen access

Katerine Rashkovsky, Danielle M Morabito, Bettye Chargin et al.

✦ AI-curated · Sources linked

In 30 seconds

This secondary analysis of a randomized clinical trial examined treatment outcomes among women veterans with military sexual trauma and posttraumatic stress disorder, comparing skills training in affective and interpersonal regulation (STAIR) with present-centered therapy (PCT). Of 161 participants, 42 identified as sexual minority women (SMW). PTSD symptoms improved in both SMW and heterosexual participants. Compared with heterosexual participants, SMW showed greater improvement in emotion regulation, maladaptive beliefs, and depression symptoms (p = .002 for each). Across sexual orientations, participants had greater benefits in STAIR; alliance and satisfaction were high in both treatments.

Key findings

  • PTSD symptoms improved in both sexual minority and heterosexual women veterans.
  • SMW improved more than heterosexual participants in emotion regulation, maladaptive beliefs, and depression symptoms (p = .002 for each).
  • Regardless of sexual orientation, participants had greater benefits in STAIR than PCT.
  • Therapeutic alliance and treatment satisfaction were high in both treatment groups, with no difference between groups.

Why it matters

The findings suggest that women veterans with military sexual trauma can improve with either of the studied therapies, while SMW may show particular gains in emotion regulation, maladaptive beliefs, and depression. The results also point to the potential value of skills-focused treatment, while underscoring the need to consider outcomes across sexual-orientation groups.

What to keep in mind

This was a secondary analysis, and the SMW subgroup included 42 participants; the abstract does not report subgroup effect sizes or confidence intervals.

Source

Published in Psychol Trauma. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.